Dopamine covalently modifies and functionally inactivates parkin

[1]  Michael Ruse,et al.  Mechanisms and Models , 2007 .

[2]  R. Hilker,et al.  Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers , 2005, Annals of neurology.

[3]  K. Lim,et al.  Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. , 2005, Human molecular genetics.

[4]  P. Lackner,et al.  Pathogenic mutations inactivate parkin by distinct mechanisms , 2005, Journal of neurochemistry.

[5]  Alberto Albertini,et al.  The neuromelanin of human substantia nigra: physiological and pathogenic aspects. , 2004, Pigment cell research.

[6]  Jian Feng,et al.  Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. , 2004, Human molecular genetics.

[7]  Takashi Uehara,et al.  Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Mark A. Wilson,et al.  The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Troncoso,et al.  S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function , 2004, Science.

[10]  Gregory A Petsko,et al.  The 1.8-A resolution crystal structure of YDR533Cp from Saccharomyces cerevisiae: a member of the DJ-1/ThiJ/PfpI superfamily. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Palmiter,et al.  Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age* , 2003, Journal of Biological Chemistry.

[12]  K. Winklhofer,et al.  Inactivation of Parkin by Oxidative Stress and C-terminal Truncations , 2003, Journal of Biological Chemistry.

[13]  P. Lockhart,et al.  RING finger 1 mutations in Parkin produce altered localization of the protein. , 2003, Human molecular genetics.

[14]  D. Sulzer,et al.  Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics , 2003, Trends in Neurosciences.

[15]  T. Dawson,et al.  Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.

[16]  Bryan L Roth,et al.  Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons* , 2003, Journal of Biological Chemistry.

[17]  Aaron Ciechanover,et al.  The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.

[18]  J. Feldon,et al.  Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[20]  P. Lansbury,et al.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.

[21]  David W. Miller,et al.  Co‐ordinate transcriptional regulation of dopamine synthesis genes by α‐synuclein in human neuroblastoma cell lines , 2003, Journal of neurochemistry.

[22]  C. Warren Olanow,et al.  Altered Proteasomal Function in Sporadic Parkinson's Disease , 2003, Experimental Neurology.

[23]  P. Brundin,et al.  Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line* , 2002, The Journal of Biological Chemistry.

[24]  Jean-François Deleuze,et al.  Complex relationship between Parkin mutations and Parkinson disease. , 2002, American journal of medical genetics.

[25]  C. Olanow,et al.  Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease , 2002, Neuroscience Letters.

[26]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[27]  Karl Herholz,et al.  The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans , 2002, Neuroscience Letters.

[28]  J. Hardy.  Faculty Opinions recommendation of The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. , 2001 .

[29]  D. Hernandez,et al.  Lewy bodies and parkinsonism in families with parkin mutations , 2001, Annals of neurology.

[30]  A. Lang,et al.  The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. , 2001, Human molecular genetics.

[31]  N. Hattori,et al.  An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.

[32]  A. Markham,et al.  Features of the Parkin/Ariadne-like Ubiquitin Ligase, HHARI, That Regulate Its Interaction with the Ubiquitin-conjugating Enzyme, UbcH7* , 2001, The Journal of Biological Chemistry.

[33]  L. Greene,et al.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Hitoshi Takahashi,et al.  An autopsy case of autosomal‐recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene , 2000, Movement disorders : official journal of the Movement Disorder Society.

[35]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[36]  M. LaVoie,et al.  Peroxynitrite‐ and Nitrite‐Induced Oxidation of Dopamine : Implications for Nitric Oxide in Dopaminergic Cell Loss , 1999, Journal of neurochemistry.

[37]  L. Elferink,et al.  Tyrosine Hydroxylase Is Inactivated by Catechol‐Quinones and Converted to a Redox‐Cycling Quinoprotein , 1999, Journal of neurochemistry.

[38]  K. Vrana,et al.  Cytotoxic and genotoxic potential of dopamine , 1999, Journal of neuroscience research.

[39]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[40]  K. Vrana,et al.  Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.

[41]  A. Lees,et al.  Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.

[42]  D. Kuhn,et al.  Dopamine Inactivates Tryptophan Hydroxylase and Forms a Redox-Cycling Quinoprotein: Possible Endogenous Toxin to Serotonin Neurons , 1998, The Journal of Neuroscience.

[43]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[44]  T. Hastings,et al.  Inhibition of Glutamate Transport in Synaptosomes by Dopamine Oxidation and Reactive Oxygen Species , 1997, Journal of neurochemistry.

[45]  M. Zigmond,et al.  Modification of Dopamine Transporter Function: Effect of Reactive Oxygen Species and Dopamine , 1996, Journal of neurochemistry.

[46]  M. Zigmond,et al.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Sulzer,et al.  Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[48]  A. Carlsson,et al.  Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species , 1986, Neuropharmacology.

[49]  L. Chia,et al.  Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease , 2005, Journal of Neural Transmission.

[50]  E. Rosengren,et al.  Detection of 5-S-cysteinyldopamine in human brain , 2005, Journal of Neural Transmission.

[51]  Robert C. Wolpert,et al.  A Review of the , 1985 .